<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01766414</url>
  </required_header>
  <id_info>
    <org_study_id>36688</org_study_id>
    <secondary_id>2011-002222-46</secondary_id>
    <nct_id>NCT01766414</nct_id>
  </id_info>
  <brief_title>In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II</brief_title>
  <acronym>VECTORII</acronym>
  <official_title>In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - A Randomized Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanquin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Excessive inflammation is associated with tissue damage caused by over-activation of the
      innate immune system. This can range from mild disease to extreme conditions, such as
      multiple organ dysfunction syndrome (MODS) and acute respiratory distress (ARDS). In marked
      contrast to adaptive immunity which is very sensitive to immune modulators such as steroids,
      the innate immune system cannot be sufficiently targeted by currently available
      anti-inflammatory drugs.

      The investigators hypothesize that pre-treatment with C1-esterase inhibitor in a human
      endotoxemia model can modulate the innate immune response.

      In this study, human endotoxemia will be used as a model for inflammation. Subjects will,
      prior to endotoxin administration, receive C1 esterase inhibitor or placebo. Blood will be
      sampled to determine the levels of markers of the innate immune response.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neutrophil phenotype and redistribution</measure>
    <time_frame>8 hrs after LPS administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytokines and other markers of inflammation</measure>
    <time_frame>8 hrs after LPS administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C1-inhibitor and complement concentration and activity</measure>
    <time_frame>8 hrs after LPS administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Innate Immune Response</condition>
  <condition>Endotoxemia</condition>
  <condition>Inflammation</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>C1-esterase inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>C1-esterase inhibitor 100 U/kg infusion followed by administration of Endotoxin 2ng/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (saline 0.9%) infusion followed by administration of Endotoxin 2ng/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C1-esterase inhibitor</intervention_name>
    <description>intravenously</description>
    <arm_group_label>C1-esterase inhibitor</arm_group_label>
    <other_name>Cetor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endotoxin</intervention_name>
    <description>intravenously</description>
    <arm_group_label>C1-esterase inhibitor</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>2 ng/kg E. coli reference endotoxin 11:H 10:K negative</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers (18-35 years old)

        Exclusion Criteria:

          -  Relevant medical history

          -  Drug-, nicotine-abuses

          -  Tendency towards fainting

          -  Hyper- or hypotension

          -  Use of any medication
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Hoeven, Prof</last_name>
    <role>Study Director</role>
    <affiliation>UMC Nijmegen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2013</study_first_submitted>
  <study_first_submitted_qc>January 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2013</study_first_posted>
  <last_update_submitted>November 27, 2014</last_update_submitted>
  <last_update_submitted_qc>November 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Endotoxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement C1s</mesh_term>
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

